NCT01218555View on ClinicalTrials.gov

Study of Everolimus (RAD001) in Combination With Lenalidomide

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 9, 2010

Primary Completion Date

November 5, 2020

Study Completion Date

November 5, 2020

Conditions
Solid Organ MalignanciesAdenoidcystic CarcinomaNeuroendocrine Tumors
Interventions
DRUG

Lenalidomide

Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.

DRUG

Everolimus

5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.

Trial Locations (2)

30303

Grady Health System, Atlanta

30322

Emory University Winship Cancer Institute, Atlanta

Sponsors

Collaborators (2)

Celgene
Novartis
All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

Emory University

OTHER

NCT01218555 - Study of Everolimus (RAD001) in Combination With Lenalidomide | Biotech Hunter | Biotech Hunter